J
Javier Molina-Cerrillo
Researcher at University of Alcalá
Publications - 58
Citations - 550
Javier Molina-Cerrillo is an academic researcher from University of Alcalá. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 9, co-authored 33 publications receiving 281 citations.
Papers
More filters
Journal ArticleDOI
Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
TL;DR: Ibrutinib has the ability to revert polarization of TCD4+ to Th1 lymphocytes to increase the cytotoxic ability of T CD8+ and to regulate tumor-induced immune tolerance by acting over tumor infiltrating cells activity and immunosuppressive cytokines release.
Journal ArticleDOI
Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy.
Olga Martínez-Sáez,Pablo Gajate Borau,Teresa Alonso-Gordoa,Javier Molina-Cerrillo,Enrique Grande +4 more
TL;DR: Treatment with HIF-2α specific antagonists, either alone or in combination with immunotherapy or other antiangiogenic agents have the potential to transform the therapeutic landscape in this tumor in the future.
Journal ArticleDOI
Tyrosine Kinase Receptors in Oncology
Jorge Esteban-Villarrubia,Juan José Soto-Castillo,Javier Pozas,María San Román-Gil,Inmaculada Orejana-Martín,Javier Torres-Jiménez,Alfredo Carrato,Teresa Alonso-Gordoa,Javier Molina-Cerrillo +8 more
TL;DR: This review is to provide a comprehensive review of the different families of TKRs and their role in the expansion of tumor cells and how TKIs can stop these pathways to tumorigenesis, in combination or not with other therapies.
Journal ArticleDOI
Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".
Teresa Alonso-Gordoa,María Laura García-Bermejo,Enrique Grande,Pilar Garrido,Alfredo Carrato,Javier Molina-Cerrillo +5 more
TL;DR: An overview of the central role of these tyrosine kinases’ activities in relevant biological processes for kidney cancer and their usefulness in RCC targeted therapy development is presented.
Journal ArticleDOI
BRAF Mutated Colorectal Cancer: New Treatment Approaches.
Javier Molina-Cerrillo,María San Román,Javier Pozas,Teresa Alonso-Gordoa,Miguel Pozas,Elisa Conde,Marta Rosas,Enrique Grande,María Laura García-Bermejo,Alfredo Carrato +9 more
TL;DR: The biology of a subgroup harboring a BRAF mutation represents approximately 10% of the patients diagnosed with colon cancer, and has morphological, clinical, and therapeutic characteristics that differ substantially from patients who do not carry this genetic alteration.